Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.68 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.68 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9599834 | 0.86 | SMARCA2 (0.86) | SMARCA2SMARCA4CNR1S1PR2 | |
| SCHEMBL9278345 | 0.83 | SMARCA2 (0.65) | SMARCA2SMARCA4GRM5HDAC4AR | |
| SCHEMBL31434913 | 0.83 | SMARCA2 (0.66) | SMARCA2SMARCA4GRM5JAK2TYK2 | |
| SCHEMBL4175713 | 0.83 | SMARCA2 (0.66) | SMARCA2SMARCA4GRM5JAK2TYK2 | |
| SCHEMBL5145795 | 0.83 | SMARCA2 (0.65) | SMARCA2SMARCA4ARJAK2TYK2 | |
| SCHEMBL119685 | 0.82 | SMARCA2 (0.79) | SMARCA2SMARCA4CNR1 | |
| SCHEMBL17804195 | 0.81 | SMARCA2 (0.64) | SMARCA2SMARCA4GRM5ARJAK2 | |
| SCHEMBL22125195 | 0.81 | SMARCA2 (1.00) | SMARCA2SMARCA4SORT1GRM5CNR1 | |
| SCHEMBL6526162 | 0.81 | CNR1 (0.51) | SMARCA2SMARCA4CNR1 | |
| SCHEMBL28821933 | 0.81 | JAK2 (0.63) | SMARCA2SMARCA4HDAC4JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| EP-4219488-A1 | METHOD FOR THE PREPARATION OF UREA COMPOUNDS AS SMARCA2/BRM-ATPASE INHIBITORS | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-4210683-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Aurigene Oncology Limited (IN) | 2023-07-19 | — | — | EP | disclosed |
| EP-3837256-B1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM-ATPASE INHIBITORS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-1898903-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-31 | — | — | US | disclosed |
| CN-101103012-A | Compounds modulating PPAR gamma type receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2008-01-09 | — | — | CN | disclosed |
| EP-1827436-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006065601-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | SMARCA2 4/4885SMARCA4 7/4885SORT1 3521/4885 |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | SMARCA2 94/4885SMARCA4 102/4885SORT1 4684/4885 |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | SMARCA2 4523/4885SMARCA4 4378/4885SORT1 4198/4885 |
| US-20080027077-A1 | Novel biaromatic compounds that modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | SMARCA2 2375/4885SMARCA4 1832/4885SORT1 2759/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | SMARCA2 3724/4885SMARCA4 3628/4885SORT1 4807/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | SMARCA2 3724/4885SMARCA4 3628/4885SORT1 4807/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | SMARCA2 4692/4885SMARCA4 4333/4885SORT1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.